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Abstract
Introduction: A number of questions remain unanswered in the field of cell therapy for acute myocardial
infarction, including what is the optimal cell type, and can therapeutic efficacy be enhanced by conditioning
regimens. In this study, we sought to address these questions by directly comparing the effect of bone marrow-
derived mesenchymal stem cells and unrestricted somatic stem cells delivered 24 hours post-myocardial infarction
and by determining if the therapeutic efficacy of unrestricted somatic stem cells could be enhanced by exposing
the cells to guiding factors before cell transplantation.
Methods: Unrestricted somatic stem cells were guided by exposure to 50 ng/mL basic fibroblast growth factor,
20 ng/mL hepatocyte growth factor and 20 ng/mL bone morphogenetic protein-2 for 24 hours. Using a Sprague-
Dawley rat model of acute myocardial infarction, we transplanted cells by intramyocardial injection 24 hours post-
myocardial infarction. Cardiac function was serially measured using echocardiography, and histological analyses of
infarct morphology, angiogenesis and apoptosis were obtained. Transcriptomic and proteomic changes were
assessed using microarray and real-time quantitative PCR.
Results: When assessed 28 days after the myocardial infarction, the delivery of mesenchymal stem cells 24 hours
post-myocardial infarction did not improve ejection fraction (P = 0.19), and did not prevent the decline in ejection
fraction observed in the absence of cell therapy (P = 0.17). The administration of unrestricted somatic stem cells
also did not improve ejection fraction (P = 0.11), but did prevent a further decline in ejection fraction (P = 0.001).
Delivery of guided unrestricted somatic stem cells significantly improved ejection fraction (P = 0.03). Guided
unrestricted somatic stem cells restored function to a greater extent than mesenchymal stem cells (P = 0.03).
The infarct area (P = 0.2), apoptosis (P = 0.07) and angiogenesis (P = 0.09) did not differ between groups.
Microarray analysis revealed that, following pre-implantation guiding, the gene groupings of mitosis, signalling and
angiogenesis were highly overrepresented, mediators of apoptosis were overrepresented, and cardiomyocyte-
associated genes were not differentially expressed.
Conclusions: These results suggest that guided unrestricted somatic stem cells have a moderate capacity to repair
cardiac damage and that they are more effective than mesenchymal stem cells in restoring cardiac function after a
myocardial infarction. The mechanism of the benefit was not fully elucidated in this study, but these observations
may be mediated by favorable dysregulation of angiogenic and apoptotic gene groupings.
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Introduction
Acute myocardial infarction (MI) results in cardiomyocyte
death and scar formation. The resulting impaired cardiac
function leads to cardiac failure and premature death.
Stem cell therapy has the potential to limit the extent of
cardiac damage by accelerating the normal healing
process, improving vascularization, inhibiting apoptosis,
and potentially regenerating cardiac muscle [1-4]. The
mechanisms of effect by which stem cells improve cardiac
function are increasingly being understood, and it is gener-
ally acknowledged that a combination of actions play a
complementary role. The ability of transplanted cells to
engraft and transdifferentiate has been shown by a number
of investigators [5-7], but the extent of engraftment is low,
and probably cannot account for the magnitude of effect,
suggesting that alternative mechanisms play at least as
important a role. One such complementary mechanism is
the paracrine effect, in that mesenchymal stem cells
(MSC) may mediate the functional improvement through
secretion of soluble cytokines and growth factors [8]. In
view of the probable significant contribution of the para-
crine effect, a number of genetic and pharmacologic
approaches have been employed to further advance the
effectiveness of cell therapy. For example, bone marrow-
derived MSC transfected with the anti-apoptotic gene Akt
and delivered via an intra-coronary route resulted in a
greater improvement in cardiac function 4 weeks post-MI
than delivery of unmodified MSC [9]. Separately, the expo-
sure of MSC to a ‘cardiopoietic cocktail’ was shown to
enhance the reparative capacity of MSC by promoting
their differentiation into a cardiac progenitor [10].
An additional method to optimize the effect of cell
therapy is through the use of alternative cell populations.
Bone marrow-derived MSC are the prototypical stem cell
population, and although generally effective, genetic
modification strategies in some studies have been
required to demonstrate a beneficial effect [9]. Cells with
a wider differentiation potential may have a greater capa-
city to repair cardiac damage than MSC. One such cell
type is the umbilical cord blood-derived unrestricted
somatic stem cell (USSC). This is considered to be a pre-
cursor of MSC, has a different surface phenotype, a wider
differentiation profile, and has the advantage of non-inva-
sive collection [11]. USSC have been shown to improve
cardiac function in small and large animal models
through a combination of autocrine and paracrine effects
[12,13], and USSC have immunosuppressive properties
that may confer protection from immune rejection [14].
These favorable features may provide additional thera-
peutic effects over MSC; however, a direct comparison of
the effectiveness of USSC and MSC has not been per-
formed, and the effect of pre-conditioning regimens on
USSC has not yet been studied.
In this study, we aim to address these questions.
Specifically, in an animal model of the intramyocardial
delivery of stem cells after MI, we compare the efficacy
of MSC with USSC; and we examine whether pre-trans-




Female Sprague-Dawley rats (Harlan Laboratories,
Blackthorn, UK) weighing 200 g were used in this study.
The experiments were approved by the Clinical
Research Ethics Committee of National University of
Ireland, Galway, and were in compliance with the Guide
for the Care and Use of Laboratory Animals as pub-
lished by the US National Institutes of Health (National
Institutes of Health publication no. 85-23, revised 1996).
The experiments were performed under a license
granted by the Department of Health and Children, in
compliance with the Cruelty to Animals Act - Revised,
1876. All procedures were performed by personnel certi-
fied by LAST-Ireland in animal welfare.
Isolation and culture of cells
Bone marrow cells were isolated from the femoral and
tibial compartments of female Sprague-Dawley rats
(Harlan Laboratories) and plated at a density of 1.5 ×
108 in T175 culture flasks. The mesenchymal cell popu-
lation was isolated based on plastic adherence. Cells
were cultured in a- Minimum Essential Medium and
F12 medium (Sigma-Aldrich, St. Louis, MO, USA) with
10% fetal bovine serum (PAA Laboratories, GmbH,
Pasching, Austria) and 1% antibiotic/antimycotic at 37ºC
in 5% CO2. Passage four cells were used in this experi-
ment. Prior to administration, cells were resuspended in
250 µL serum-free F12 media (Sigma).
Unrestricted somatic stem cells culture
Passage four human USSC (Cell-Eng Tech, Coralville, IA,
USA) were cultured in BulletKit (Sigma). Prior to admin-
istration, cells were resuspended in 250 µL serum-free
F12 media (Sigma). For in vitro experimentation, USSC
were plated at a density of 4 × 105 cells/cm2. After
24 hours, the media was changed, and fresh media was
supplemented with 50 ng/mL basic fibroblast growth fac-
tor (bFGF), 20 ng/mL hepatocyte growth factor (HGF)
and 20 ng/mL bone morphogenetic protein-2 (BMP2)
(all from R&D Systems, Minneapolis, MN, USA). For
in vivo experimentation, USSC were guided in an identi-
cal fashion and were detached with trypsin 0.025% after
24 hours. Expansion media was supplemented with
50 ng/mL bFGF, 20 ng/mL HGF and 20 ng/mL BMP2
24 hours prior to cell administration.
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Myocardial infarct model and cell administration
MI was performed as previously described. Briefly, Spra-
gue-Dawley rats were anesthetized with isoflurane
reduced to 5% with oxygen, intubated, and maintained
on 2% isoflurane for the duration of surgery. Following a
lateral thoracotomy, the left anterior descending coron-
ary artery was identified and ligated 2 mm distal to the
left auricle with a 7-0 polypropylene suture. MI was con-
firmed by blanching of the myocardium distal to the
suture. Animals were randomly assigned to receive 4 ×
106 MSC 24 hours post-MI, 4 × 106 USSC 24 hours post-
MI or 4 × 106 guided USSC (cUSSC) 24 hours post-MI.
Cells were delivered in five equal aliquots by an intra-
myocardial injection to the border zone of the infarct.
Control animals received an equal volume of F12 without
cells, or no intervention post-MI. We assigned our
groups as MSC, USSC, cUSSC and Media and MI only.
Echocardiographic analysis
An echocardiogram was performed at baseline, and at
48 hours post-MI in the case of animals not receiving
cells, and 24 hours after cell administration in those
randomized to cell therapy. A third echocardiogram was
performed at sacrifice, 28 ±2 days after cell administra-
tion. A short-axis image of the left ventricle at the level
of the papillary muscles was recorded with a 10 Hz elec-
tronic phased-array transducer and a VIVID5 Ultra-
sound System(General Electric, Fairfield, CT,USA).
Ejection fraction (EF) was calculated as {(LVEDD)3 -
(LVESD)3}/(LVEDD)3, where LVEDD is the left ventri-
cular end-diastolic dimension and LVESD is the left
ventricular end-systolic dimension. EF was expressed as
a percentage, and animals were included in the study if
their EF decreased by >15% from its baseline. One ani-
mal was excluded due to its EF varying by more than
three standard deviations from the mean.
Assessment of infarct size
Myocardial fibrosis was detected by Masson’s trichrome
staining at 28 ±2 days post-MI. Briefly, hearts were har-
vested, and 15 to 18 slices of 5 µm thickness were pre-
pared from midcavity to apex. A similar region of each
heart was photographed (Olympus DP70, Olympus Cor-
poration, Tokyo, Japan) with the aid of an inverted bright-
field research microscope (Olympus IX71, Olympus Cor-
poration) at resolutions of 1.25×, 4× and 10×, and images
were recorded using the programs Image ProPlus and
Analysis D.
Angiogenesis assay and terminal
deoxynucleotidyltransferase-mediated 2’-deoxyuridine 5’-
triphosphate nick end labelling analysis
Capillary density was assessed by immunohistochemical
staining with Von Willebrand factor antibody (1:800,
Abcam, Cambridge, MA, USA). Angiogenesis was
assessed by measurement of radial diffusion and length
density. Using Image ProPlus software, eight images
were obtained and a grid of a known area was placed
over each image. Calculation of the number of intersec-
tions of vessels with a marker on the grid allowed calcu-
lation of the radial diffusion and length density.
Apoptotic cardiomyocytes in the border zone of the
ischemic region were evaluated by terminal deoxynucleoti-
dyltransferase-mediated 2’-deoxyuridine 5’-triphosphate
nick end labelling (TUNEL) assay with an in situ cell
death detection kit (Chemicon S7100 kit, Chemicon,
Temecula, CA, USA). The percentage of TUNEL-positive
cells in the border zone and infarct zone were compared
to the TUNEL-positive cells in the normal myocardium.
In vitro phenotypic and genotypic analysis of unrestricted
somatic stem cells
Immunofluorescence
Immunostaining for cardiac troponin T (1:750, Abcam)
and b-myosin heavy chain (1:100, Abcam) was per-
formed. Slides were counterstained with 4,6-diamino-2-
phenylindole-containing mounting medium (Sigma).
Microarray
RNA was isolated (RNeasy Mini Kit, Qiagen, Hilden, Ger-
many) and concentrated (RNeasy MinElute Cleanup Kit,
Qiagen) in accordance with the manufacturer’s guidelines.
The integrity of RNA was evaluated with an Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Samples with an RNA Integrity Number >9.0 were labelled
and hybridized. Genome-wide expression profiling was
carried out using whole human genome 4 × 44 k oligo
microarrays (Agilent). Linear amplification from 500 ng
total RNA and spike-in-controls (Agilent) was performed
using the Agilent Low RNA Input Linear Amplification
Kit Plus, one colour. Amplified RNA was directly labelled
by incorporation of Cy3-labelled cytidine triphosphate.
Labelled RNA was purified with RNeasy Mini spin col-
umns (Qiagen) and 1.65 μg labelled RNA was used for
chemical fragmentation and hybridization (Gene Expres-
sion Hybridization Kit, Agilent). Assembly of the gasket/
slide-sandwich in the hybridization chamber (Agilent),
and hybridization in the Microarray Hybridization oven
(Agilent) was performed according to manufacturer
instructions. Slides were scanned using an Agilent DNA
Microarray Scanner. Data extraction of the resulting array
images was performed using the Feature Extraction soft-
ware (Agilent, Version 9.1) and GeneSpring GX v11 (Agi-
lent) was used for statistical analysis. All samples included
in downstream analysis were required to pass Agilent’s
QC Metrics. The global gene list was filtered to remove
non-expressed genes flagged as absent. To detect differen-
tially expressed genes, a Welch T-test using Benjamini and
Hochberg multiple testing correction with an adjusted
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P-value <0.05 was used, along with a fold change cut off of
2.0. Functional analysis was performed using the Database
for Annotation, Visualisation and Integrated Discovery
[15,16]. All microarray data are MIAME compliant, as
detailed on the Microarray Gene Expression Data Society
website [17]. The raw data have been deposited in the
MIAME compliant database ArrayExpress [18] under
accession number [E-MEXP-3638]. Data have been
released in the public domain upon acceptance of this
manuscript.
RNA profiling
Real-time quantitative PCR was performed using a Taq-
Man PCR kit (Applied BioSystems, Foster City, CA, USA)
in triplicate. Threshold cycle values were determined
using the 2-ΔΔCT method, normalized to human-specific
b-actin (Applied BioSystems). Representative upregulated
and downregulated genes, as identified on microarray ana-
lysis, and pre-defined cardiac-specific genes were analysed.
These genes included kazal-type serine protease inhibitor
domain-containing protein 1 (KAZALD1 [GenBank:
NM_030929.4]; Hs00934805_m1), extracellular matrix
protein 2, female organ and adipocyte specific (ECM2;
[GenBank:NM_001197295]; Hs00946422_m1), v-erb-a
erythroblastic leukemia viral oncogene homolog 4 (avian)
(ERBB4; [GenBank:NM_001042599.1]; Hs00171783_m1),
guanine nucleotide binding protein (G protein), alpha 14
(GNA14; [GenBank:NM_004297.3]; Hs00388871_m1),
dehydrogenase/reductase (SDR family) member 2
(DHRS2; [GenBank:NM_005794.3]; Hs00195090_m1),
galanin prepropeptide (GAL; [GenBank:NM_015973.3];
Hs01032384_m1), tetraspanin 2 (TSPAN2; [GenBank:
NM_005725.4]; Hs00194836_m1), troponin T type 2 (car-
diac) (TNN2; [GenBank:NM_000364.2]; Hs00945605_m1),
GATA binding protein 4 (GATA4; [GenBank:NM_
002052.3]; Hs00171403_m1), heart and neural crest deri-
vatives expressed 1 (HAND1; [GenBank:NM_004821.2];
Hs00231848_m1), NK2 homeobox 5 (NKX2.5; [GenBank:
NM_004387.3]; Hs00231763_m1) and myosin, heavy
chain 7, cardiac muscle, beta (MYH7; [GenBank:NM_
000257.2]; Hs01110632_m1).
Statistical analysis
The echocardiographic data and infarct histology mea-
surements were expressed as mean ±standard error (SE).
Within group comparisons were analysed using one-
sided t-test. Multiple groups were analysed with a one-
sided analysis of variance and Bonferroni post hoc testing,
using the statistical software PASW/SPSS® Version 18.0
(IBM, Chicago, IL, USA). A P-value of <0.05 was consid-
ered statistically significant. For analyses in which
Levene’s test of homogeneity of variances was significant
(P <0.05), Brown-Forsythe and Welch testing was per-
formed. Based on an expected improvement in EF of 10%
(with a standard deviation of 9%) in the cUSSC group,
30 animals were required to provide a power of 90% and
a two-sided alpha of 0.05 to detect this difference. Data
analysis of the microarray study was performed as
described above.
Results
Comparison of the effect of mesenchymal stem cells and
unrestricted somatic stem cells administered 24 hours
post-myocardial infarction
Assessment of cardiac function
The first measurement of cardiac function was performed
48 hours after MI. There was no difference between
groups in the EF measured at this time-point, but the
MSC group did have a trend towards a higher EF than the
other groups. The administration of MSC post-MI did not
have a significant effect on cardiac function, as measured
by echocardiography. MSC administration resulted in an
EF at sacrifice of 55.3% (SE: 3.9%; n = 6), which was not
statistically significantly higher than the EF observed in
the MI only (n = 5) group (39.7%; SE: 4.3%; P = 0.17), or
the Media (n = 6) group (41.2%; SE: 3.9%; P = 0.24) at the
same time-point (Figure 1a). The EF at sacrifice in the
MSC group was 5.7% lower (SE: 5.2%; P = 0.19) than the
EF post-MI (Figure 1b).
The EF measured at sacrifice in the group receiving
USSC (66.5%; SE: 3.9%; n = 6) was significantly greater
than the EF measured at sacrifice in the control groups of
MI only (P = 0.001), and Media (P = 0.001) (Figure 2a).
The administration of USSC post-MI resulted in an
improvement in EF of 11% (SE: 5.25%) at sacrifice, relative
to the EF measured post-MI (Figure 2b), although this
improvement was not statistically significant (P = 0.11).
The EF at sacrifice in the USSC group was 11.2% higher
(SE: 5.5%) than the EF at sacrifice in the MSC group
(55.3%; SE: 3.9%), but this difference was also not signifi-
cant (P = 0.76) (Figure 2c).
As the EF post-MI in the MSC group showed a trend
towards being higher than the EF in the other groups, we
evaluated the change in EF within each group (the differ-
ence in EF at sacrifice relative to the EF post-MI), and
compared this across groups. This ‘absolute change’ was
not significantly different between the MSC group and the
USSC group (P = 0.48) (Figure 3). Thus, in this study, the
administration of USSC ameliorated the decline in EF that
is observed post-MI, and this effect was not observed fol-
lowing MSC delivery. However, USSC were not more
effective than MSC in terms of restoring cardiac function.
Assessment of infarct size
Infarct area was obtained by measuring infarct length and
infarct width. The mean infarct areas of the MI only
group (18.6 mm2; SE: 2.6 mm2) and the Media group
(20.7 mm2; SE: 2.4 mm2) were not different from the
infarct areas of the MSC group (14.4 mm2; SE: 2.4 mm2)
or the USSC group (17.2 mm2; SE: 2.4 mm2). There was
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no difference in infarct area following administration of
MSC or USSC (P = 1.0) (Figure 4a).
Angiogenesis assay and TUNEL analysis
Angiogenesis was assessed by the extent of radial diffu-
sion in the border zone of each infarct, and expressed as
a mean. The average radial diffusion in the MI only
group (29.0 μm; SE: 3.3 μm) and Media group (24.3 μm;
SE: 0.7 μm) was compared with the MSC group (21.0
μm; SE: 0.9 μm) and the USSC group (22.9 μm; SE: 1.9
μm). Testing for non-parametric data revealed no signif-
icant difference between groups (Figure 4b).
In addition, the percentage of apoptotic cells in the
border zone of infarcts, as assessed by TUNEL staining,
was not different between groups (P = 0.07), with simi-
lar percentages of TUNEL-positive cells in the MI only
group (2.2%; SE: 0.9%), the Media group (2.8%; SE:
0.8%), MSC group (6.2%; SE: 1.0%) and USSC group
(4.3%, SE: 0.9%) (Figure 4c).
Effect of unrestricted somatic stem cells and guided
unrestricted somatic stem cells administered at 24 hours
post-myocardial infarction
Assessment of cardiac function
The administration of cUSSC resulted in a significantly
higher EF at sacrifice (65.6%; SE: 4.3%; n = 5) relative to
MI only and Media (P = 0.003 for both comparisons)
(Figure 5a). The administration of cUSSC resulted in an
increase in EF of 20.7% (SE: 5.7%; P = 0.03) at sacrifice,
relative to the EF measured 24 hours after cell administra-
tion (Figure 5b). The absolute change in EF in the cUSSC
group (an increase of 20.7%) was significantly greater than
that observed in the control group of MI only (P = 0.03)
and Media (P = 0.01).
Comparing the cUSSC group with both the unmodified
USSC group and the MSC group, there was no difference
in the absolute change between the cUSSC group and the
unmodified USSC group (9.7%; SE: 7.8%, P = 1.0), but
there was a significant difference in the absolute change
between the cUSSC group and the MSC group (P = 0.03)
(Figure 6). This demonstrates that, although USSC did not
generate a significantly beneficial effect when compared to
MSC, cUSSC induced a greater therapeutic effect, as mea-
sured by echocardiography.
Assessment of infarct size
The mean infarct area of the cUSSC group (12.8 mm2; SE:
2.6 mm2) was not significantly different from the infarct
areas in the MI only group (P = 1.0), the Media group
(P = 0.36), or the USSC group (P = 1.0) (Figure 7a).
Although there was no difference in infarct size between
groups, this study was not powered a priori to detect this
difference. Indeed, a comparison across all groups revealed
a significant correlation between infarct area and EF (r =
-0.55, P = 0.002) (Figure 8), with no evidence of clustering.
Of the two largest infarcts, one was observed in the USSC
group, and one in the Media group. Of the three smallest
infarcts, one each was observed in each of the cell groups.
Angiogenesis assay and TUNEL analysis
The radial diffusion in the group receiving cUSSC (21.6
μm; SE: 0.6 μm), was not significantly different than the
radial diffusion in all other groups, as described above
(Figure 7b).
The analysis of TUNEL staining also revealed the lack
of effect of cUSSC on apoptosis (3.4%; SE: 1.0%) com-
pared with all other groups (Figure 7c).
In vitro phenotypic and genotypic analysis of unrestricted
somatic stem cells
Immunofluorescence
The guiding regimen used in this study was 24 hour
culture of USSC in media supplemented with 50 ng/mL
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Figure 1 Ejection fraction in mesenchymal stem cell group and
control groups. (a) The EF at sacrifice in the MSC group was not
statistically significantly higher than the EF at sacrifice in the control
groups. (b) There was a slight, but non-significant, decline in EF at
sacrifice in the MSC group compared with the EF post-MI. MI Only:
n = 5; Media: n = 6; MSC: n = 6. EF: ejection fraction; MI: myocardial
infarction; MSC: mesenchymal stem cells.
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bFGF, 20 ng/mL HGF and 20 ng/ml BMP2. This regi-
men did not result in enhanced expression of cardiac-
specific markers (cardiac troponin T and b-myosin
heavy chain) as assessed by immunofluorescence.
Microarray analysis
To determine genomic differences of cUSSC compared
with unmodified USSC, their genome-wide gene expres-
sion profiles were studied using whole human genome 4
× 44 k oligo microarrays (Agilent). There was significant
differential expression of 736 genes, with a fold change
of ≥2.0 (adjusted P-value <0.05), with 388 upregulated
and 348 downregulated. Functional analysis of differen-
tially expressed genes was performed using the Database
for Annotation, Visualisation and Integrated Discovery.
From the functional annotation chart derived from this
analysis, the three most significant terms are ‘mitosis’,
‘cell division’, and ‘blood vessel development’. The func-
tional terms ‘vascular development’ and ‘blood vessel
morphogenesis’ were also highly represented, as were
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Figure 2 Ejection fraction in unrestricted somatic stem cells group and control groups. (a) The EF in the USSC group was significantly
higher at sacrifice compared to the control groups (P = 0.001). This is accounted for by the improvement in EF within this group (+11%), in
comparison with the decline of approximately 5% in the control groups. (b) The improvement of 11% in the USSC group was not statistically
significant (P = 0.11). (c) There was no difference in the EF at sacrifice between the MSC group and the USSC group. MI Only: n = 5; Media: n =
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Figure 3 Absolute change in ejection fraction across groups.
The USSC group was the only group to show an improvement in
EF by the time of sacrifice. USSC delivery thus was considered to
ameliorate the decline in EF observed in the control groups and the
MSC group. MI Only: n = 5; Media: n = 6; MSC: n = 6; USSC: n = 6.
EF: ejection fraction; MI: myocardial infarction; MSC: mesenchymal
stem cells; USSC: unrestricted somatic stem cells.
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the terms ‘angiogenesis’ and ‘regulation of angiogenesis’.
Further evidence of the angiogenic profile of cUSSC was
seen in the functional annotation chart, which revealed
that the third most highly represented gene grouping
was ‘angiogenesis’, after ‘mitosis’ and ‘signalling’. Indivi-
dual genes related to angiogenesis that were significantly
upregulated included fibroblast growth factor homolo-
gous factor 2 (FHF2), which was upregulated approxi-
mately seven-fold; fibroblast growth factor 13 (FGF13),
upregulated over four-fold; placental growth factor
(PGF), coding for a vascular endothelial growth factor-
like protein, upregulated over four-fold; and both
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Figure 4 Analysis of Infarct Size, Angiogenesis and Apoptosis
In the Control Groups, MSC Group and USSC Group. (a) Infarct
size, (b) angiogenesis and (c) apoptosis. There was no significant
difference in the infarct size, angiogenesis or apoptosis between
groups. MI Only: n = 5; Media: n = 6; MSC: n = 6; USSC Group: n =
6. MI: myocardial infarction; MSC: mesenchymal stem cells; USSC:
unrestricted somatic stem cells.


















Figure 5 Ejection fraction in the guided unrestricted somatic
stem cells group and control groups. (a) The EF at sacrifice in
the cUSSC group was significantly higher than the EF at sacrifice in
the control groups. (b) The EF at sacrifice in the cUSSC group was
significantly higher than the EF at 48 hours post-MI. MI Only: n = 5;
Media: n = 6; cUSSC Group: n = 5. cUSSC: guided unrestricted
somatic stem cells; EF: ejection fraction; MI: myocardial infarction.
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angiopoietin-like 5 and platelet-derived growth factor
subunit A-related peptide were upregulated over three-
fold. Graphical presentations of these findings are pre-
sented in Figure 9.
Another of the most significantly expressed gene-sets
included ‘regulation of apoptosis’ and ‘programmed cell
death’. Although in this study we did not observe a
reduction in the extent of apoptosis after administration
of cUSSC, the microarray finding suggests that cell
death regulation may play a role in mediating the posi-
tive effects of cell therapy. Also of note is the observa-
tion that primitive and mature markers of cardiac
differentiation, including GATA4, Nkx2.5, b-myosin
heavy chain and cardiac troponin T, were not signifi-
cantly differentially expressed in cUSSC. The absence of
dysregulation of the aforementioned cardiac genes was
confirmed by RT-PCR.
Discussion
The evolution of cell therapy for cardiac disease has seen a
gradual change in the cell populations that have been
administered, from unfractionated bone marrow mono-
nuclear cells in early reports [19] to bone marrow-derived
MSC in subsequent reports [20], and recently to more car-
diac-specific cell populations [10]. As the cell population
has become more refined, the benefits of administration
have been improving, with recent reports of the successful
administration of cells of a cardiac specification (either
autologous or guided), in both pre-clinical and clinical stu-
dies [21,22]. The variety of cell populations that have been
studied demonstrates that the optimal cell population has
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Figure 6 Absolute change in ejection fraction across treatment
groups. The change in EF across the three treatment groups is
presented. There is a slight decline in EF in the MSC group, and
improvements in EF in the USSC and cUSSC groups. The extent of
change in the cUSSC group (20.7%) was significantly greater than
the change in the MSC group (-5.7%) (P = 0.03). MSC: n = 6; USSC:
n = 6; cUSSC: n = 5. cUSSC: guided unrestricted somatic stem cells;
EF: ejection fraction; MSC: mesenchymal stem cells; USSC:
unrestricted somatic stem cells.
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Figure 7 Analysis of Infarct Size, Angiogenesis and Apoptosis
In the Control Groups, USSC Group and cUSSC Group. (a)
Infarct size, (b) angiogenesis and (c) apoptosis. There was no
significant difference in the infarct size, angiogenesis or apoptosis
between groups. MI Only: n = 5; Media: n = 6; USSC: n = 6; cUSSC:
n = 5. cUSSC: guided unrestricted somatic stem cells; MI: myocardial
infarction; MSC: mesenchymal stem cells; USSC: unrestricted somatic
stem cells.
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cardiac specific may be associated with a greater effective-
ness. In this study, we observed results that are generally
consistent with these prior observations. We studied three
distinct cell populations: bone marrow-derived MSC,
umbilical cord blood-derived USSC, and USSC that had
been guided by pre-implantation exposure to factors con-
sidered to induce cardiac specification. The administration
of cUSSC to an animal model of acute MI was associated
with a beneficial effect on cardiac function.
Using echocardiography as a primary determinant of
effectiveness, we observed that the delivery of MSC
post-MI did not result in significant recovery of cardiac
function post-MI, and it did not impact on the contin-
ued decline in cardiac function post-MI. Although many
studies have shown that the delivery of bone marrow-
derived MSC improves cardiac function, this observation
has not been replicated by all investigators. For example,
in one study, it was shown that hearts receiving unmo-
dified MSC perform no better than untreated infarcted
hearts [23]. The mechanism for this is postulated to be
related to the intense inflammatory environment
induced by infarction, in that transplanting cells into
this environment may overwhelm the ability of these
cells to survive. Modification of cells to enhance the
expression of the pro-survival gene Akt1 was required
before improvements in survival capacity were observed
[9]. Furthermore, unmodified MSC, which do not have a
cardiac specification, may have reduced ability to repair
cardiac damage as they do not have a transcriptome
that is conducive to cardiac repair. Pre-treating cells
with a cardiopoietic cocktail has been shown to induce
cardiac specification, and significantly enhances the
cells’ ability to restore cardiac function, as measured by
echocardiography [10].
We evaluated the relative effectiveness of USSC, com-
pared with MSC, to determine whether this cell popula-
tion provides a greater potential for cardiac repair. We
observed that the administration of USSC post-MI was
only moderately effective, in that it prevents the decline
in cardiac function that is observed in the absence of cell
Figure 8 Correlation between ejection fraction and infarct size. Pooling all groups together, there is a significant correlation between EF
and infarct size (r = -0.55; P = 0.002). There was no evidence of clustering of groups. Of the two largest infarcts, one was observed in the USSC
group, and one in the Media group. Of the three smallest infarcts, one each was observed in each of the cell groups. EF: ejection fraction; LVEF:
left ventricular ejection fraction; USSC: unrestricted somatic stem cells.
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therapy. This echocardiographic outcome was not sup-
ported by significant changes in infarct size, angiogenesis
or apoptosis however. Also, the administration of USSC
was not more beneficial than the administration of MSC,
and we cannot conclude that unmodified USSC are a
substantially more effective therapy. Although there is
evidence that umbilical cord blood-derived stem cells
have intrinsic cardiomyogenic potential, which may pro-
vide a significant advantage over alternative cell popula-
tions [24], this potential advantage was not realized in
our study.
In this study, we did not administer immunomodulatory
agents to the animals receiving human USSC therapy, and
therefore the possibility exists that an immune response
could partially explain our results. However, while the
administration of human MSC to animal models is asso-
ciated with a significant immune response, umbilical cord
blood-derived cells are more immune privileged and pro-
mote a much lower immune response [25]. Specifically,
after the xenogeneic transplantation of umbilical- and
bone marrow-derived stem cells, umbilical cord-derived
stem cells were shown to be less immunogenic, cause less
 (a) 
(b) 
Figure 9 Graphical representation of the (a) upregulated and (b) downregulated gene groupings based on enrichment scores. The 388
upregulated and 348 downregulated genes are grouped according to their functional classification, and subdivided to specifically demonstrate
the proportion involved in apoptosis and angiogenesis/cardiogenesis.
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immune activation, and get rejected more slowly than
bone marrow-derived cells. Separately, a recent review of
the xenotransplantation of human adipose tissue-derived
stem cells concluded that immunocompatability was
observed in studies of the transplantation of human cells
into rats, mice, dogs and rabbits [26]. Furthermore, in a
study of the allogeneic activity of USSC [14], USSC are
shown to be conditionally immunosuppressive and their
immunological properties to be regulated by the local
environment. Therefore, although in our study we did not
administer immunomodulatory therapy, we do not believe
that this had a significant impact on our observations.
Previous studies have demonstrated that cells that have
been guided prior to implantation are more effective than
unmodified cells. This finding has been observed in bone
marrow-derived cells, and has not yet been described in
USSC. The guiding factors used in this study (bFGF, HGF
and BMP-2) were selected because, in embryonic tissue,
they act on the primitive mesoderm to direct these cells
down a cardiac pathway [27]. However, we did not induce
dysregulation of genes involved in cardiac muscle genera-
tion. To successfully induce cardiomyogenesis, it is possi-
ble that either a wider selection of guiding factors is
needed, or culture conditions need to be more cardio spe-
cific. It has previously been shown that treatment of MSC
with similar factors (bFGF, BMP-2, insulin-like growth
factor 1 resulted in an increase in expression of cardiac-
specific markers only when co-cultured in the presence of
neonatal cardiomyocytes [28]. Others have similarly
reported that differentiation of bone marrow stromal cells
into cells with a cardiac phenotype requires intercellular
communication with myocytes [29], and that connexin-43,
a protein required for gap junction formation, may med-
iate the cytoprotective effect of cell therapy. In our study,
the absence of co-culture may have limited the ability of
USSC to become cardiomyocytes.
In cUSSC, we observed transcriptomic changes that
were consistent with upregulation of both pro-angiogenic
and anti-apoptotic genes, suggesting that angiogenesis and
programmed cell death play central roles in mediating the
benefit of this therapy. Others have shown that new vessel
formation is a central component of cardiac repair [30]; in
the present study, functional annotation clustering
revealed that angiogenic gene-sets were among the most
upregulated clusters. Specific genes associated with angio-
genesis that were upregulated in our study included FHF2,
FGF13 and PGF, providing evidence of the enhanced
angiogenic potential of the guided cells.
Consistent with the partial angiogenic genotype that
was generated in cUSSC, we observed a modestly benefi-
cial effect of cUSSC administration on cardiac function,
as measured by echocardiography. Administration of this
cell population improved cardiac function post-MI, and
it also had a slightly greater effect than the administration
of MSC. The mechanism for this benefit was not eluci-
dated in the present study, as histological measurements
of explanted hearts did not differ between groups.
Although the transcription profile of cUSSC was consis-
tent with them having a greater angiogenic potential, this
observation was not supported by our histology. A possi-
ble explanation for this is that our study was powered on
the basis of anticipated improvements in cardiac function
as measured by echocardiography, rather than histologi-
cal parameters. Indeed, while the difference in angiogen-
esis between groups was not statistically significant, with
a P-value of 0.09, it is conceivable that a larger cohort
may have allowed statistical significance to be achieved.
Further research on this observation is warranted, and it
will be necessary to include assessments of the efficiency
of cell engraftment and cell survival. Although prior stu-
dies have shown engraftment and survival rates of 3% at
14 days after intramyocardial cell delivery [31], we did
not directly assess this parameter in the present study.
We also did not evaluate a group of animals receiving
guided MSC, as this has been performed previously [27],
and would not represent a novel aspect to our study.
Given the greater plasticity of USSC [11], it could be
assumed that the benefit of guiding USSC would exceed
that observed following guided MSC delivery. Indeed, we
observed that cardiac function improved following the
administration of cUSSC, but as a direct comparative
group was not included, we cannot conclude that guiding
MSC would have had a lesser effect. With further study,
an optimal guiding regime may be identified, which
would allow a direct comparison across cell types.
The absence of an effect of cell therapy on infarct size
has been described in a small number of studies, and is
multifactorial [32]. Possible reasons for this lack of effect
include insufficient cell survival in the peri-infarct milieu
that allows for a decrease in infarct size being observed.
While a small number of cells persist, and their presence
is enough to affect cardiac function, they are not present
in sufficient numbers to decrease the extent of fibrosis or
induce the formation of new cardiac muscle. In this study,
we did not evaluate the survival of USSC in cardiac tissue.
Another possible reason for the absence of an observed
benefit was the range of infarct sizes observed within each
group. Our study was primarily powered to detect a
change in EF using echocardiography, and was not pow-
ered to assess infarct size a priori. However, we did
observe that there was a significant correlation between
infarct size and EF that suggests that the inclusion of a lar-
ger number of animals may have allowed detection of sig-
nificant decreases in infarct size in line with significant
increases in EF. Finally, there is no consensus regarding
the optimal dose of cells (and indeed route of administra-
tion [33]), and although we have previously investigated
alternative doses and found the dose used in this study to
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be optimal, it remains possible that lower doses in small
animals may be more beneficial.
Conclusions
There is a moderately beneficial effect on cardiac function
after the administration of cUSSC in an animal model of
acute MI. This benefit is greater than that observed after
the administration of MSC, using cardiac function mea-
sured by echocardiography as the marker of improvement.
In this study, we did not demonstrate that infarct mor-
phology differed between groups, but the cUSSC group
did have significant favourable dysregulation of angiogenic
and apoptotic gene-sets, which may have contributed to
their effectiveness. Based on the results of this study,
further research on the therapeutic effect of USSC and
cUSSC is warranted.
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